Azenta Files 8-K for Reg FD Disclosure, Financial Exhibits

Ticker: AZTA · Form: 8-K · Filed: Jan 31, 2024 · CIK: 933974

Complexity: simple

Sentiment: neutral

Topics: regulation-fd, financial-statements, corporate-governance

TL;DR

**Azenta just dropped an 8-K for Reg FD and exhibits, signaling new info is out.**

AI Summary

Azenta, Inc. filed an 8-K on January 31, 2024, primarily to disclose information under Regulation FD and to file financial statements and exhibits. This filing indicates that the company is providing information that may be material to investors, ensuring fair and broad dissemination. For investors, this matters because it suggests Azenta is proactively sharing important updates, which can impact their perception of the company's transparency and future performance.

Why It Matters

This filing ensures that all investors receive important company information simultaneously, preventing selective disclosure and promoting a fair market.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure filing and does not inherently present new risks, but rather ensures transparency.

Analyst Insight

Investors should look for subsequent announcements or the specific exhibits filed to understand the substance of the Regulation FD disclosure and any financial updates.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

What is the primary purpose of Azenta, Inc.'s 8-K filing on January 31, 2024?

The primary purpose of Azenta, Inc.'s 8-K filing on January 31, 2024, is to disclose information under Regulation FD and to file financial statements and exhibits, as indicated by 'ITEM INFORMATION: Regulation FD Disclosure' and 'ITEM INFORMATION: Financial Statements and Exhibits'.

What is Azenta, Inc.'s trading symbol and on which exchange is its common stock registered?

Azenta, Inc.'s trading symbol is AZTA, and its Common Stock, with a $0.01 par value, is registered on The Nasdaq Stock Market, as stated under 'Securities registered pursuant to Section 12(b) of the Act'.

What is the business address and phone number of Azenta, Inc. as listed in the filing?

The business address of Azenta, Inc. is 200 Summit Drive, Burlington, MA 01803, and its business phone number is (978) 262-2400, according to the 'BUSINESS ADDRESS' and 'BUSINESS PHONE' sections.

What was Azenta, Inc.'s former company name before its most recent change?

Before its most recent name change to Azenta, Inc. on 20190521, the company was formerly known as Brooks Automation, Inc., as detailed in the 'FORMER COMPANY' section.

What is the Central Index Key (CIK) for Azenta, Inc.?

The Central Index Key (CIK) for Azenta, Inc. is 0000933974, as specified in the 'COMPANY DATA' section of the filing.

Filing Stats: 664 words · 3 min read · ~2 pages · Grade level 12.8 · Accepted 2024-01-31 16:34:38

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. As previously announced, effective October 1, 2023, Azenta, Inc. (the "Company") realigned its organizational structure to three principal business segments to enhance its commercial strategy for accelerating growth and to enable additional profitability initiatives. The Company's operating and reportable segments effective in the first quarter of fiscal 2024 (which align with how the Company's Chief Operating Decision Maker manages the business, allocates resources, and assesses performance) consist of the following: Multiomics. The Multiomics business resources operate under a single business unit that provides genomic and other sample analysis services, including gene sequencing and gene synthesis. Sample Management Solutions. Sample & Repository Solutions, Ultracold Systems, and Consumables and Instruments resources operate as a single business unit offering end-to-end sample management services and products. B Medical Systems. B Medical Systems business resources operate as a single business unit focused on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations. For informational purposes, included in Exhibit 99.1 to this report, and incorporated into this Item 7.01 by reference, is the Company's historical recast of segment information that reflects the segment changes noted above for fiscal years 2023 and 2022 and the quarters therein. Limitation on Incorporation by Reference . The information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference i

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Supplemental Information – Historical Recast of Segment Information 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AZENTA, INC. /s/ Jason W. Joseph Date: January 31, 2024 Jason W. Joseph Senior Vice President, General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing